Crisps, breakfast cereals next for Novozyme acrylamide reduction

By Rod Addy

- Last updated on GMT

Breakfast cereals could be next on the acrylamide reduction agenda
Breakfast cereals could be next on the acrylamide reduction agenda

Related tags: Nutrition, Glucose, Acrylamide, Novozymes

Novozymes aims to extend work on its Acrylaway solution to cut acrylamide in food into other food categories, having tackled areas such as crackers, biscuits, coffee and, most recently, French fries.

Acrylamide has been linked in animal studies to increased risk of cancer. It is created as a natural by-product of the Maillard reaction between sugar and an amino acid called asparagine when food is subjected to high heat.

Speaking to FoodNavigator at the Institute of Food Technologists Annual Meeting & Expo 2012 in Las Vegas, Flemming Mark Christensen, senior global marketing manager at Novozymes, said: “We have launched two new [acrylamide reduction] applications in the past year, one for coffee and one for French fries. But there’s also work to be done in other categories like potato chips and breakfast cereals.”

Food allergies and intolerances

The company saw considerable future benefits in continuing its use of enzymes to remove potentially harmful substances from food and drink he said. Another area it was looking at was the use of enzymes to counteract food allergies and intolerances, such as lactose intolerance.  Novozymes had worked on the use of lipases to produce trans fat free oils, he added.

Food ingredient solutions and premix firm DSM is conducting similar work with enzymes to combat food intolerances, having recently launched its Tolerase L enzyme as a dietary supplement for lactose intolerant consumers. Tolerase L breaks down lactose into glucose and galactose. DSM Nutritional Products has partnered Novozymes in the field of animal feed enzymes.

Christensen said the challenge now was to upscale production of its Acrylaway solution to a mass commercial level. “It’s absolutely feasible. We are in discussions with potential customers on how to implement these technologies.”​ Novozymes had been conducting trials to that end in the past six months, he said.

Related topics: Science

Related news

Show more

Follow us

Products

View more

Webinars